Aytu Biopharma (AYTU) Revenue (2013 - 2026)

Aytu Biopharma (AYTU) has reported Revenue for 14 consecutive years, with $12.4 million the latest figure, recorded in Q1 2026.

• On a quarterly basis, Revenue fell 32.74% year-over-year to $12.4 million in Q1 2026; TTM through Mar 2026 was $56.6 million, a 14.04% decrease from a year earlier, with the FY2025 full-year figure at $66.4 million, up 1.84% from the prior year.
• Revenue was $12.4 million for Q1 2026 at Aytu Biopharma, down from $15.2 million in the prior quarter.
• Over five years, Revenue peaked at $30.7 million in Q2 2023 and troughed at $12.4 million in Q1 2026.
• A 5-year average of $19.5 million and a median of $17.8 million in 2023 frame the typical range for Revenue.
• Across the five-year window, Revenue slumped 52.52% in 2024 and soared 31.57% in 2025, its largest moves.
• Over 5 years, Revenue stood at $26.3 million in 2022, then slipped by 28.66% to $18.7 million in 2023, then dropped by 13.48% to $16.2 million in 2024, then dropped by 6.51% to $15.2 million in 2025, then declined by 18.16% to $12.4 million in 2026.
• The last three Revenue figures came in at $12.4 million (Q1 2026), $15.2 million (Q4 2025), and $13.9 million (Q3 2025), per Business Quant data.